web analytics
April 28, 2015 / 9 Iyar, 5775
At a Glance

Posts Tagged ‘medicine’

Israeli Scientists Testing Cannabis Treatment for Diabetes

Wednesday, April 22nd, 2015

Israeli scientists at the Hebrew University of Jerusalem have tracked down a specific chemical compound in the cannabis plant, a cannabinoid called “cannabidiol” that researchers say can be used to treat diabetes.

The best source for cannabidiol, or CBD as it is called, appears to be hemp – a plant with no potential for abuse and which has no psychoactive properties.

Dr. Raphael Mechoulam is the researcher known for discovering CBD as well as his collaboration with researcher Dr. Ruth Gallily, also from Hebrew University. It was Mechoulam who discovered receptors for cannabinoids not only in the brain, but elsewhere as well, in other body tissues. The discovery opened up an entirely new area of research into how coucannabinoids could be modified to fit different receptors, and thereby treat different illnesses.
Meanwhile, the discovery is already heading to market. An Israeli company called ISA Scientific has recently signed a worldwide collaboration and licensing deal with Yissum, the technology-transfer company of Hebrew University, as well as Hadasit, the technology-transfer company of Hadassah Medical Organization of Jerusalem, and KIR, the Kennedy Trust for Rheumatology Research in the UK.

The agreement backs the creation and development of specific therapies using cannabidiol (CBD) by the inter-disciplinary research team headed by Mechoulam. KIR director and immunologist Sir Marc Feldman is also involved in the effort, as are Hadassah researchers and physicians Chaim Lotan, Lolan Weiss and Ronen Durst.

Phase I clinical trials on dosing and safety are now underway in Israel, according to ISA Scientific CEO Mark J. Rosenfeld. “Arrangements for Phase 2 trials on treating diabetes and chronic pain are in process,” he said in a statement.

Rosenfeld added that the firm’s Israeli research and development team had been working on the issue of an oral delivery system. Very little CBD reaches the bloodstream when taken by mouth, according to an article posted to the Israel21c news website, necessitating a more efficient system. The problem was solved “with propietary nanotechnology” currently being integrated into the firm’s clinical trials.

According to Rosenfeld, CBD seems to have no major side effects, and apparently does not affect activities such as work, school, sports or driving. More to the point, the company says in a statement on its website that it is working towards creating a way to “control diabetes into the medical market place.

“CBD may even help prevent diabetes.”

ISIS Fighters in Syria May Be Felled By Lesions (Not Legions)

Tuesday, April 7th, 2015

To everything in its season, and so the tide has turned once more in the Middle East. What bombing could not end, God’s Mighty Hand may accomplish with a tiny fly.

Fighters for Daesh, the Islamic State in Iraq and Syria (ISIS) terrorist organization, are now being attacked by a terrible skin disease called Leishmaniasis.

Two types of the disease have been identified in the region: Leishmaniasis major, and Leishmaniasis tropica. Both are carried and transmitted by parasites hosted on sand flies in the environment.

Although an article by Hadassah Medical Center says the disease cannot be transferred from person to person, researchers found in a study published in The Journal of Infectious Diseases in 2003 that such transmission may indeed be possible, since parasites can jump.

An outbreak of Cutaneous Leishmaniasis (CL) in the Galilee region of northern Israel in 2003 was discussed in the article which noted 33 cases in four villages and in the city of Tiberias were diagnosed between 1996 and 2003. The disease, which spread through parasites and sand flies, had mutated from its predecessor, Leishmania major and other tropical diseases.

CL due to Leishmania major as opposed to MCL and VL (two other forms) was defined as being zoonotic and much more difficult to treat. The cutaneous lesions were said to last much longer and the disease was described as life-threatening if it progressed to visceral leishmaniasis (VL). The study found that rock hyraxes found in northern Israel around Lake Kinneret were the most probable reservoir hosts for the parasites that carry the disease.

If that is true, then so too is it likely that ISIS fighters are facing a difficult time because it was mentioned that the parasites also jump from person to person, as well from the living animals around them.

More to the point, the disease is caused by poor hygiene and bad living conditions; it has affected at least 100,000 people in Syria, according to the latest reports. It can result in open flesh wounds, ulcers, an enlarged spleen and liver, anemia and ultimately lead to death.

Although it’s pretty easy to treat, there are very few medics and trained medical professionals left in Syria and ISIS-controlled Iraq who know how to manage it.

Volunteers with the Doctors Without Borders organization of course know how to handle it – but since ISIS is deeply dedicated to kidnapping, torturing and murdering those helping hands, it’s not likely they are going to see any help from them. Ditto for Syrian government troops for the same reason.

Ironically, a new project was launched last year by the Israeli Pharmaseed research company to track down a treatment for this disease.

Four partners were recruited for the project. Two of the four — the Dead Sea and Arava Science Centers – identified 70 plant extracts that may be relevant for fighting the parasite.

The Swiss Tropical and Public Health Institute, meanwhile, will test the efficacy of the extracts on leishmaniasis samples.

Pharmaseed is coordinating the project and is responsible for safety tests, and for assessing the potential efficacy of the extracts being tested.

Jordan University of Science and Technology Prof. Nabil Hailat will carry out advanced live and clinical trials (on humans) in Jordan, which should yield the test results.

Israeli Scientist Finds Omega-3 Reduces Smoking

Monday, November 10th, 2014

Want to stop smoking, for real, and you just can’t seem to manage it on your own but hate the thought of patches and “chemicals” ?

A new study conducted by an Israeli scientist  has found that Omega-3 reduces a smoker’s craving for nicotine, thereby making it easier to quit the unhealthy habit.

The study was headed by Dr. Sharon Rabinovitz Shenkar, head of the addictions program at University of Haifa’s school of criminology and the department of psychopharmacology laboratory at Bar Ilan University.

Subjects participating in the study were asked to take five capsules per day for 30 days of Omega-3 950 produced by Solgar. A second group, used as controls, received placebos. Neither group was asked to stop smoking.

The groups included 38 smokers ages 18 to 45 who somked at least 10 cigarettes per day during the past year, and an average of 14 cigarettes per day. The average subject had been smoking for at least 11 years.

Levels of nicotine craving and consumption were measured using a series of scales at the beginning of the study, after 30 days of treatment and after 60 days (30 days after stopping the Omega-3 capsules.)

“The substances and medications currently used to help people reduce and quit smoking are not very effective and cause adverse effects that are not easy to cope with,” Shenkar observed.

“The findings of this study indicated that Omega-3, an inexpensive and easily available dietary supplement with almost no side effects, reduces smoking significantly,” she added.

Among myriad other health problems, smoking also reduces the levels of essential fatty acids in the brain – especially that of Omega-3. When the body is deficient in Omega-3, the cellular structure of nerve cells is damaged, and it interrupts neurotransmission in areas of the brain involved with feeling pleasure and satisfaction, Shenkar explained.

These areas are essential in reward and decision-making, and are very important in the process of the development, maintenance and relapse of the addict and inability to stop smoking.

“In simpler terms, Omega-3 deficiency makes it harder for the smoker’s body to deal with its craving for another cigarette.

The findings of the new study show that while no difference was found between the groups at the beginning of the study, after thirty days the smokers who had taken Omega-3 reduced their cigarettes by an average of two a day (an eleven-percent decrease), even though they were not asked to change their smoking habits in any way. No less important, they showed a significant decrease in nicotine craving. After another thirty days of not taking anything, cigarette cravings increased slightly but still remained significantly lower than their initial level. In other words, the craving to smoke cigarettes did not return to the baseline level even a month after stopping to take the supplement. The group receiving the placebo did not show any significant changes in their craving levels or in the number of cigarettes they smoked a day during the sixty days.

“Earlier studies have proven that an imbalance in Omega-3 is also related to mental health, depression and the ability to cope with pressure and stress,” Shenkar emphasized. “Pressure and stress, in turn, are associated with the urge to smoke. It is also known that stress and tension levels rise among people who quit smoking. Despite all this, this connection between all these factors had not been studied until now.”

The finding that people who were not interested in stopping to smoke showed such a significant change reinforces the assumption that taking Omega-3 can help smokers to regulate their addiction and reduce their smoking, Shenkar pointed out.

Chocolate May Be Sweet Solution for Memory Problems Age 50+

Tuesday, October 28th, 2014

Are you over fifty and finding it hard to keep track of your car, your keys or new faces these days?

According to the findings of a small study published in the October 1, 2014 volume of the journal Nature Neuroscience, chocolate may improve memory skills normally lost with age.

Healthy subjects ages 50 to 69 performed better on a memory test after drinking a mixture high in cocoa flavanols for three months than those who drank a mixture low in flavanols.

Cocoa flavanols are anti-oxidants, which led the drinkers to perform the same as people 20 to 30 years younger on a pattern recognition test involving the kind of skill used when remembering the face of someone you just met, or the place you parked your car.

Researchers found that people in the high-flavanol group exhibited increased function in the “dentate gyrus” area of the brain’s hippocampus – the area linked to this type of memory skill.

According to the study’s principal investigator Dr. Scott A. Small, a neurologist at Columbia University Medical Center, those who drank the cocoa flavanol mixture performed 25 percent better than the low-flavanol control group.

The area of the hippocampus that is impaired early in Alzheimer’s disease – the entorhinal cortex – showed no increased activity.

But it would take a monumental amount of chocolate to reach the level of flavanols necessary to achieve any effect, doctors say.

To reach 138 milligrams of epicatechin (the daily dose of the high flavanol group), one would have to eat about 100 grams of baking chocolate or unsweetened cocoa powder – about 300 grams of dark chocolate a day.

Consider the incredible amount of fat and calories involved, and the cost-benefit ratio.

Is it really worth it?

Age-related memory decline may be different, and that flavanols may not help people with Alzheimer’s, even if they help those with age-related memory loss, researchers point out.

There were other factors involved that may have affected the study outcomes, including the size of the cohort and other food items consumed by the subjects and controls.

Nevertheless, good news about chocolate in any form is always good news for chocolate lovers.

Right?

Israeli ALS treatment Gets ‘Fast-Track’ FDA Designation

Saturday, October 11th, 2014

(JNS.org) Stem cell treatment developed by Israeli company BrainStorm Cell Therapeutics has been designated by the U.S. Food and Drug Administration (FDA) as a “fast-track” treatment of amyotrophic lateral sclerosis (ALS).

The treatment, called NurOwn, is currently undergoing mid-stage clinical trials in Jerusalem and in the U.S. on patients with ALS, which is also known as Lou Gehrig’s Disease. The FDA’s designation will speed up patients’ access to the treatment.

“The receipt of fast-track designation from the FDA is an acknowledgement of the unmet medical need in ALS,” BrainStorm Chief Executive Tony Fiorino said Tuesday, according to Reuters. “What is so valuable about fast track designation to a small company like BrainStorm is the opportunity to have increased meetings with and more frequent written communication from the FDA,” he said, adding that few other cellular therapies have received FDA approval.

The ALS Association reports that 5,600 people in the U.S. are diagnosed each year with the disease.

Despite Rockets: PA, Gaza Arabs treated at Haifa Hospital

Thursday, July 10th, 2014

Palestinian terrorists may be firing one rocket at Israeli civilians every 10 minutes, but that hasn’t altered Jews’ approach to treating Arab victims of Hamas from Gaza and the Palestinian Authority. Currently,  three adults and eight children from Gaza are hospitalised at Rambam Hospital, in addition to three adults and two children from the PA. In addition, seven PA Arabs have been treated this week at the hospital’s outpatient clinics. Additional patients from Gaza are scheduled for treatments later this week.

Most of the hospitalized children are in the pediatric oncology or nephrology wards. Of these, the majority is under the age of three, and they are accompanied by relatives. Additional medical problems and the need for long-term treatment makes lengthy hospitalizations standard for these children.

Yazid Falah, the hospital’s coordinator for Palestinian patients, said medical cooperation between Israel and the PA continues despite the rocket fire.

“Despite the security situation, and despite the fact that both sides are fighting, all continues as usual in the realm of medical cooperation. Even in times of war we continue to receive patients and give them the care they need—children and adults,” Falah said.

Falah added that while treatments for all patients have continued unabated, the fighting between Israel and Hamas has created an unmistakably difficult situation for many patients.  “On the one hand they are in Israel and see the consequences of Hamas’ actions and how people get hurt on this side of the border. On the other hand, they fear for the lives of their family members back in Gaza,” Falah said. “There are those who have told me they are ashamed of what Hamas is doing; others say they are afraid of how people will talk and look at them here in the hospital. Some say they are afraid to return to Gaza. Others just don’t know what to think. They have a life there and see the kind of life people have here.

“At the end of the day, they simply want to live in peace, but it is clear to them that the situation has changed. They believe the situation is only going to get worse,” Falah said.

“When the hostilities escalated, the Palestinian patients feared a cold reception,” says Falah, “we explained that would never happen in an Israeli hospital. Here you see people and not nationalities. Many times, Israeli patients reach out to their Palestinian “neighbors” to help them feel more comfortable and to encourage them. Eventually, all are in the same boat.”

Israeli Treatment for Gaucher Disease Approved in Canada

Monday, June 2nd, 2014

Canada has approved Elelyso, a new Israeli treatment for Type 1 Gaucher disease. The medication received kosher certification from the Orthodox Union, according to Pfizer, which distributes the drug in the United States.

Gaucher disease is an inherited disease in which the body does not store lipids correctly. This results in a buildup of the fatty substances in cells, certain organs and sometimes in the bone tissue, causing damage to organs such as the spleen, liver and brain.

Elelyso (taliglucerase alfa) is a long-term enzyme replacement therapy produced by Protalix Biotherapeutics Inc., which treats the disease in both adults and children.”

Elelyso was approved by the U.S. FDA on May 1, 2012 and received marketing authorization from the Israeli Ministry of Health on September 12, 2012. It is also approved in a number of other countries, including Brazil and Uruguay.

“With the Canadian approval of Elelyso, the drug is now approved for patients in more than ten countries across the globe,” said Protalix SVP product development Dr. Einat Brill Almon.

“This validates the ability and safety of ProCellEx, our manufacturing platform technology, which we are currently using to develop additional enzyme replacement therapies.”

Printed from: http://www.jewishpress.com/news/breaking-news/israeli-treatment-for-gaucher-disease-approved-in-canada/2014/06/02/

Scan this QR code to visit this page online: